Phase II trial for F2G’s antifungal drug following EU approval
European Pharmaceutical Review | January 11, 2017
The European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted orphan drug status to UK biotech firm F2G’s lead clinical candidate, F901318, for the treatment of invasive Aspergillosis and rare mould infections caused by Scedosporium species.